 FSD Pharma Inc CSE:HUGE, NASDAQ:HUGE announced it has submitted a Clinical Trial Application CTA for a planned Phase-1 clinical trial for Lucid-MS, a candidate for the treatment of multiple sclerosis MS. In a statement, FSD Pharma called Lucid-MS a first-in-class neuroprotective compound with a novel mechanism action that has shown to prevent myelin degradation, which can cause MS and other neurodegenerative diseases. 